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Background: Endocannabinoids are involved in normal cognition, and dysfunction in cannabinoid-receptor-
mediated neurotransmission has been suggested in a variety of neurological and psychiatric pathologies. The
type 1 cannabinoid receptor (CB1) is widely expressed in the human central nervous system. The objective of
this study was to quantify the test–retest reproducibility of measures of the PET ligand [11C]MePPEP in order
to assess the stability of CB1-receptor quantiﬁcation in humans in vivo.
Methods: Fifteen healthy subjects (eight females; median age 32 years, range 25 to 65 years) had a 90-minute
PET scan on two occasions after injection of a median dose of [11C]MePPEP of 364 MBq. Metabolite-corrected ar-
terial plasma input functions were obtained for all scans. Eight ROIs, reﬂecting different levels of receptor densi-
ties/concentrations, were deﬁned automatically: hippocampus, anterior cingulate gyrus, inferior frontal gyrus,
caudate nucleus, globus pallidus, nucleus accumbens, thalamus, and pons. We used seven quantiﬁcation
methods: reversible compartmental models with one and two tissue classes, two and four rate constants, and
a variable blood volume term (2kbv; 4kbv); model-free (spectral) analyses with and without regularisation, in-
cluding onewith voxel-wise quantiﬁcation; the simpliﬁed reference tissuemodel (SRTM)with pons as a pseudo-
reference region; and modiﬁed standard uptake values (mSUVs) calculated for the period of ~30–60 min after
injection. Percentage test–retest change and between-subject variability were both assessed, and test–retest re-
liability was quantiﬁed by the intraclass correlation coefﬁcient (ICC). The ratio of binding estimates pallidum:
pons served as an indicator of a method's ability to reﬂect binding heterogeneity.
Results: Neither the SRTM nor the 4kbv model produced reliable measures, with ICCs around zero. Very good
(N0.75) or excellent (N0.80) ICCswere obtainedwith the othermethods. Themost reliablewere spectral analysis
parametric maps (average across regions ± standard deviation 0.83 ± 0.03), rank shaping regularised spectral
analysis (0.82 ± 0.05), and the 2kbv model (0.82 ± 0.09), but mSUVs were also reliable for most regions
(0.79 ± 0.13). Mean test–retest changes among the ﬁve well-performing methods ranged from 12 ± 10% for
mSUVs to 16% for 2kbv. Intersubject variability was high, with mean between-subject coefﬁcients of variation
ranging from 32 ± 13% for mSUVs to 45% for 2kbv. The highest pallidum:pons ratios of binding estimates
were achieved by mSUV (4.2), spectral analysis-derived parametric maps (3.6), and 2kbv (3.6).
Conclusion: Quantiﬁcation of CB1 receptor availability using [
11C]MePPEP shows good to excellent reproducibility
with several kinetic models and model-free analyses, whether applied on a region-of-interest or voxelwise basis.
Simple mSUV measures were also reliable for most regions, but do not allow fully quantitative interpretation. [11C]
MePPEP PET is well placed as a tool to investigate CB1-receptor mediated neurotransmission in health and disease.
Crown Copyright © 2014 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).ERMEP — Imagerie du vivant, 59 boulevard Pinel, 69677 Lyon/Bron, France. Fax: +33 4 72 68 86 10.
dis.org (A. Hammers).
r Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Endocannabinoids and their receptors are involved in a wide spec-
trum of conditions, e.g. addiction (Bossong et al., 2009) and epilepsy
(Gofﬁn et al., 2011), as well as in normal cognition (Hampson et al.,
2011).
Two transmembrane G-protein coupled receptor types in the
endocannabinoid system have been discovered. Type 1 (CB1) is found
in the central nervous system (CNS) and in neuronal and non-
neuronal tissues outside the CNS (Matsuda et al., 1990). Abundantly
expressed in presynaptic glutamatergic and GABAergic terminals
(Katona and Freund, 2008), CB1 receptors have a heterogeneous CNS
distribution. High concentrations are found in the cerebral cortex,
hippocampus, caudate nucleus and putamen, substantia nigra pars
reticulata, globus pallidus, entopeduncular nucleus, the molecular
layer of the cerebellum and in pain pathways of brain and spinal cord
(Herkenham et al., 1990; Irving et al., 2002). However, the thalamus
and most of the brainstem show low concentrations (Herkenham
et al., 1990).
In the preclinical setting, a wide range of CB1-selective radioligands
have been used successfully in vitro, such as [3H]CP-55,940 (Devane
et al., 1988, 1992), [3H]SR141716A (Petitet et al., 1996), and [35S]GTPγS
(Grifﬁn et al., 1998); and also in vivo, such as (−)-5′-[18F]-Δ8-THC
(Charalambous et al., 1991), [123I]AM251 (Gatley et al., 1996), [123I]
AM281 (Gatley et al., 1998), [11C]OMAR ([11C]JHU75528) (Horti et al.,
2006), [11C]MePPEP (Yasuno et al., 2008), [11C]/[18F]-PipISB (Finnema
et al., 2009) and [11C]CB-119 (Hamill et al., 2009). In vivo human brain
CB1 availability has recently become quantiﬁable with PET and the use
of tracers such as [18F]MK-9470 (Burns et al., 2007), [11C]OMAR (Wong
et al., 2010), [11C]MePPEP (Terry et al., 2009), and [18F]FMPEP-d2 (G.E.
Terry et al., 2010b).
MePPEP ((3R,5R)-5-(3-methoxy-phenyl)-3-((R)-1-phenyl-
ethylamino)-1-(4-triﬂuoro-methyl-phenyl)-pyrrolidin-2-one) is a
CB1-selective inverse agonist. [11C]MePPEP has high and stable brain
uptake in vivo. Despite its moderately high lipophilicity (measured
LogD7.4 = 4.8) (Yasuno et al., 2008), its speciﬁc binding is relatively
high with N85% in monkey brain and 65% determined using CB1 knock-
out mouse brain (Terry et al., 2008, 2010b; Yasuno et al., 2008).
One reproducibility study with [11C]MePPEP has been performed in
humans so far, involving eight test–retest scans (Terry et al., 2009) after
injection of high doses of [11C]MePPEP (~650 MBq). Only standard up-
take values and distribution volumes derived from compartmental
modelling were examined.
In the present study we calculated the reproducibility of various
parameters to describe CB1 receptor availability with [11C]MePPEP, in-
cluding compartmental modelling techniques, spectral analysis vari-
ants, a simpliﬁed reference tissue model, and simple mSUVs, in
regions representative of various CB1 receptor concentrations in 15
healthy volunteers.
Materials and methods
Subjects
Ethical approval was obtained from the London — Surrey Borders
Research Ethics Committee, and permission to undertake the study
from the UK's radiation protection agency (ARSAC). Seventeen healthy
subjects were recruited and gave written informed consent. Exclusion
criteria were: history or presence of psychiatric or systemic medical
condition, inability to provide informed consent, claustrophobia, any
contraindication for undergoing MR, positive urine drug test, positive
urine pregnancy test, general practitioner's (family doctor's) advice
against participation, regular medication, use of cannabis within the
previous threemonths or onmore than ﬁve occasions over the subject's
lifetime, and pathological modiﬁed Allen's test for patency of the ulnar
artery (Allen, 1929; Cable et al., 1999; Slogoff et al., 1983). From thissample two were excluded: one subject with pathological modiﬁed
Allen's test; another withdrew consent for the retest scan. Hence, a
total of ﬁfteen healthy subjects (8 females; median age 32 years,
range 25 to 65 years),without history of either systemicmedical or psy-
chiatric conditions or substance abuse were scanned twice. Demo-
graphic data are detailed in Table 1. All subjects underwent a urine
drug screen cassette test for 11-nor-Δ9-THC, morphine, amphetamine,
benzoylecgonine (the main metabolite of cocaine), methamphetamine
and oxazepam (Monitect©; BMC, California, U.S.A.) prior to PET
scanning. All female patients of childbearing age underwent a urine
pregnancy test.
Radiochemistry
[11C]MePPEP was synthesised on site by Hammersmith Imanet fol-
lowing a procedure described previously (Yasuno et al., 2008). Details
of the injectate are listed in Table 1.
PET data acquisition
PET scans were acquired on a Siemens/CTI ECAT EXACT HR + 962
camera (Knoxville, TN, USA) in 3D mode. Ten-minute transmission
scans for attenuation correction were obtained prior to dynamic
emission scans using a rotating 137Cs point source. Each dynamic ac-
quisition was 90 min long and consisted of 35 frames of increasing
length (1 × 30″, 6 × 10″, 3 × 20″, 3 × 30″, 3 × 60″, 6 × 120″, 8 × 300″
and 3 × 600″). 30 s after the scan start, [11C]MePPEP was injected as
an intravenous bolus injection of ~370 MBq (median 364 MBq, range
316–399 MBq; Table 1). Subjects were scanned on two separate days
with a median interval of 24 days (range 1 to 309; Table 1).
The head position was maintained throughout and monitored with
the camera's positioning laser. If movement was noticed, subjects
were repositioned and underwent a second transmission scan at the
end of the dynamic scan. To compensate for head movement during
dynamic scans, we used a post hoc frame-by-frame realignment
method, as described later (section “PET data quantiﬁcation”). Data
were reconstructed using FORE (Defrise et al., 1997) and 2D FBP
(ramp ﬁlter, kernel 2.0 mm FWHM). Voxel sizes of reconstructed im-
ages were 2.092 × 2.092 × 2.42 mm.
Input function derivation
Continuous and intermittent blood samples were collected to allow
the subsequent generation of metabolite-corrected arterial plasma
time–activity curves (TACs) (Hammers et al., 2008). During the ﬁrst
15 min bloodwaswithdrawn continuously at a rate of 300ml/h and ra-
dioactivity measured in a BGO detection system (Jones et al., 1994). To
quantify plasma andwhole blood radioactivity, aswell as to allowquan-
tiﬁcation of the parent fraction of the radiotracer, intermittent discrete
(10 ml) samples were taken with heparinised syringes before the scan
(baseline) and at the following time points after scan start: 3, 5, 10,
15, 20, 30, and 50 min. At 75 min, a larger 17 ml sample was taken to
allow quantiﬁcation despite radioactivity decay. Parent fraction quanti-
ﬁcation was not possible at 90 min; hence at this time point only three
millilitres was withdrawn for plasma and whole blood radioactivity
measurement. Continuous plasma input functions (IF) were derived
by cross-calibration and combination of the continuous and discrete
data,multiplicationwith theﬁtted plasma-over-blood ratio, and correc-
tion for parent radiotracer fraction, as described in detail in previous
studies (Hammers et al., 2007a; Jones et al., 1994).
MRI data acquisition, analysis and generation of ROIs
All subjects had 3D T1 weighted MRI scans with approximately
millimetric voxel sizes on a Phillips Intera 3 Tesla (3 T) MRI scanner
(Best, The Netherlands) at the Robert Steiner MRI Unit, Hammersmith
Table 1
Subjects' demographic and injectate details. BMI = Body Mass Index; Min = minimum; Max = maximum.
Subject no. Age Gender BMI Scan interval (days) Dose (MBq) Radiochemistry purity (%) Co-injected mass (μg) Speciﬁc activity (MBq/nmol)
1 28 M 23 24 365 98 4.2 39
364 98 6.2 27
2 44 M 28 23 375 96 3.0 56
376 99 4.3 40
3 42 M 25 122 356 96 2.3 70
373 100 2.3 72
4 26 M 24 1 361 98 3.4 48
366 98 2.7 61
5 31 M 24 19 353 98 4.2 38
355 99 2.7 60
6 27 F 21 309 367 99 4.6 37
363 97 1.7 99
7 32 F 36 37 351 100 3.2 50
316 100 8.3 17
8 65 F 22 23 355 97 2.3 69
371 96 4.0 42
9 27 M 22 67 369 98 3.9 43
366 98 3.1 54
10 29 F 23 4 360 97 9.7 17
364 100 5.8 29
11 57 M 30 30 373 97 2.9 60
399 96 5.0 37
12 61 F 36 93 361 96 1.8 92
349 96 1.6 97
13 63 F 29 12 384 97 3.5 50
380 98 3.3 52
14 25 F 31 156 364 97 2.4 69
357 100 4.4 37
15 62 F 24 10 362 97 1.4 122
366 97 3.3 51
Median 32 24 24 364 98 3.3 98
Interquartile range
(25th-75th)
27–61 23–30 12–93 356–372 97–99 2.4–4.3 38–69
Min 25 21 1 316 96 1.4 17
Max 65 36 309 399 100 9.7 122
153D.A. Riaño Barros et al. / NeuroImage 97 (2014) 151–162Hospital, for co-registration and ROI deﬁnition. There was no visible
structural abnormality on any of the T1-weighted images.
T1-weighted images were segmented into tissue classes using the
statistical parametrical mapping software SPM8 (Statistical Parametric
Mapping, Wellcome Trust Centre for Neuroimaging, UCL, London,
www.ﬁl.ion.ucl.ac.uk/spm) under MATLAB© 7.4 (MathWorks).
The T1-weighted images were also anatomically segmented
using MAPER (multi-atlas propagation with enhanced registration;
Heckemann et al., 2010). Using high-dimensional image registration,
30 MRI data sets, each associated with manually determined labels of
83 regions (Gousias et al., 2008; Hammers et al., 2003), were propagat-
ed to the target brain. Label fusion was used to obtain 83 regions of in-
terest (ROIs) in target space (Heckemann et al., 2006).
The T1-weighted images and corresponding MAPER-derived indi-
vidual segmentations aswell as individual greymatter (GM) probability
images were co-registeredwith each subject's corresponding processed
PET summation image for test and retest scans separately. For the corti-
cal ROIs, the individual atlases in PET space were then multiplied with
the grey matter probability maps thresholded at 0.5 using Analyze©
8.1 biomedical imaging software (Mayo Clinic 2002). These regions of
interest were then used to sample the dynamic or parametric images.Manual delineation of the pons
Because the pons is not included in the 83 regions obtained via
MAPER, we delineated it manually using Analyze 8.1 (Fig. 1).
We evaluated the test–retest reliability of the quantiﬁcation
methods (see “PET data quantiﬁcation” section) in a selection of eight
bilateral ROIs in total.We chose representative regionswith high CB1 re-
ceptor concentrations; the grey matter masked cortical structures —
hippocampus, anterior cingulate gyrus, and inferior frontal gyrus; andthe subcortical structures in their entirety, i.e. not grey matter masked
(Heckemann et al., 2011)— caudate nucleus, globus pallidus, and nucle-
us accumbens. In addition, two regions with low concentration of CB1
receptors were evaluated: the thalamus and the manually deﬁned (en-
tire) pons. The data from left and right homologueswere averaged prior
to quantiﬁcation.
PET data quantiﬁcation
All dynamic PET imageswere de-noised and corrected formovements
frame-by-frame using wavelets in Piwave 8.0 (Studholme et al., 1996;
Turkheimer et al., 1999). The frame starting at 4 min (frame 10) was
used as reference due to its high signal-to-noise ratio and likelihood of
subjects staying still during the ﬁrst minutes of the scan. The ﬁrst 93 s
(frames 1 to 6) were not motion corrected due to their low signal-to-
noise ratio. The remaining frames (7 to 35) were automatically re-sliced
and re-concatenated into a new dynamic image (Hammers et al., 2007a).
A binary contiguous mask encompassing the entire brain and ex-
tending approximately 10 mm beyond the outer cortical boundary
was created semi-automatically using Analyze 8.1 and applied to both
dynamic and summed radioactivity-weighted images (ADD images) to
reduce computation time.
Regional quantiﬁcation of distribution/binding/uptake was then
performed. In all following analyses, assessment was based on the
same ROIs. Binding parameters were calculated directly for the ROI
TAC data, except in the “classic” spectral analysis, where the additional
aim was the assessment of the quality of parametric maps for use in
voxel-by-voxel analyses, and the parametric map itself was sampled
using the same ROIs:
1. Compartmental models, requiring arterial IFs (section
“Compartmental models, requiring 1 arterial IFs”):
Fig. 1.Manual delineation of the pons on MRI. (a) Sagittal view, (b) coronal view, A — Anterior, R — right. The pons was ﬁrst delineated on sagittal views, followed by coronal and axial
views, with the following limits; anterior/ventral: cisterna interpeduncularis and basilar artery (1); posterior/dorsal: ﬂoor of the fourth ventricle (2); superior: a line was drawn from the
ﬂoor of the fourth ventricle below the superior cerebellar peduncle (3) along the lower limit of the cerebral peduncle, to the indentation between the pons and themidbrain (4); inferior: a
line was drawn from the ﬂoor of the fourth ventricle above the inferior peduncle (6) to the upper limits of the olive and pyramid of the medulla oblongata (7), i.e. to the indentation be-
tween the pons and medulla oblongata (8); on coronal view: following anatomical boundaries of pons, which are clearly visible; on axial view: following delineation in both sagittal and
coronal views, the pons is now clearly delineated, and the axial view is used for veriﬁcation. [5— posterior cerebral artery].
154 D.A. Riaño Barros et al. / NeuroImage 97 (2014) 151–162• Reversible two-compartment (one tissue compartment) model
with variable blood volume (2kbv) (section “Reversible two-
compartment (one tissue compartment)modelwith two rate con-
stants and a variable blood volume (2kbv)”)
• Reversible three-compartment (two tissue compartment) model
with variable blood volume (4kbv) (section “Reversible three-
compartment (two tissue compartment) model with four rate
constants and a variable blood volume (4kbv)”)
2. Model-free analyses, requiring arterial IFs (section “Model-free
analyses, requiring arterial IFs”):
• “Classic” (non-regularised) spectral analysis (SA), applied to ROI
time-activity data (section ‘“Classic” (non-regularised) SA’).
• “Classic” SA, applied on a voxel-by-voxel basis to create parametric
maps of VT, which were then sampled in the same ROIs as for
the other methods (section “Sampling parametric VT images
obtained voxel-by-voxel using spectral analysis (“Classic” SA)”).
• Rank shaping regularisation of spectral analysis (SA; section
“Directly obtainingVT values fromROI datawith SA and rank shap-
ing regularisation”)
3. Methods not requiring arterial IFs (section “Methods not requiring
an arterial IF”):
• Simpliﬁed reference tissuemodel (SRTM) using pons as a pseudo-
reference tissue (section “Simpliﬁed reference tissue model using
pons as a pseudo-reference tissue”)
• (Regional) modiﬁed standard uptake values (mSUVs) (section
“Modiﬁed standard uptake values (mSUVs)”)
Compartmental models, requiring arterial IFs
Reversible two-compartment (one tissue compartment) model with two
rate constants and a variable blood volume (2kbv). In this model, three
microparameters are derived: K1 is the inﬂux of the ligand from the
plasma to the tissue compartment containing free, non-speciﬁcally
bound, and speciﬁcally bound ligand, k2 is the efﬂux constant from
the ROI back to plasma (Cunningham et al., 1991; Huang et al., 1980),
and bv is a variable blood volume term. VT is then calculated according
to the compartmental model equation (Watabe et al., 2006):
VT ¼ K1=k2: ð1Þ
Reversible three-compartment (two tissue compartment) model with four
rate constants and a variable blood volume (4kbv). K1 and k2were calcu-
lated as for the 2kbv compartmental model described above; inaddition, two additional rate constants were estimated to describe
transfer relating to the third compartment: k3, which describes the
transfer from the free and non-speciﬁcally bound compartment to the
speciﬁcally bound (third) compartment; and k4, which describes the
opposite transfer (Cunningham et al., 1991; Huang et al., 1980). Again,
a variable blood volume term was also computed. According to com-
partmental model equations (Gunn et al., 2001; Watabe et al., 2006):
VT ¼ K1=k2 1þ k3=k4ð Þ: ð2Þ
Model-free analyses, requiring arterial IFs
“Classic” (non-regularised) SA. Volumes of distribution (VTs) (Innis et al.,
2007) for each ROI were obtained from the dynamic images and the
metabolite-corrected IFs using spectral analysis (SA) (Cunningham
and Jones, 1993; Cunningham et al., 1993; Turkheimer et al., 1994).
The fast frequency boundary was kept at the default value of 0.1 s−1.
The theoretical slow frequency boundary is given by the decay constant
of 11C (t½≈ 20 min, decay constant 0.0005663 s−1; log10 =−3.25).
Based on previous work with another tracer with relatively slow kinet-
ics (Hammers et al., 2007a), we changed this to 0.00063 s−1 (log10 =
−3.20) in order to reduce noise.
Sampling parametric VT images obtained voxel-by-voxel using spectral
analysis (“Classic” SA). Parametric images of [11C]MePPEP VT were
obtained from the dynamic images and the metabolite-corrected
IFs using spectral analysis (SA; Cunningham and Jones, 1993;
Cunningham et al., 1993) and receptor parametric mapping software
(RPM6; Aston et al., 2001; Gunn et al., 1997) with the same fast and
slow frequency boundaries as above. The resulting parametric maps of
VT values were then sampled in the eight selected ROIs.
Directly obtaining VT values from ROI data with SA and rank shaping
regularisation. VT values were generated directly from dynamic data
sampled using ROIs with rank shaping (RS; orthogonalized-functional-
base) regularisation of SA (Turkheimer et al., 2003) using in-house
“Clickﬁt” software. As previously described by Turkheimer et al.
(2003), we used the metabolite-corrected IF, a logarithmically spaced
basis, an exponential range of bases extending to−3.2, and the regional
tissue TAC. TACs were weighted according to (Gunn et al., 1998):
Wi ¼ Li=Ti for frame i ¼ 1;2;3…35ð Þ ð3Þ
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Fig. 2. Example plot showing a VT of 12 obtained for the hippocampus from the VT(R)
plateau (see section "Directly obtaining VT values from ROI data with SA and rank shaping
regularisation").
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of true coincidences (per second)].
The VT for each ROI was then obtained as the plateau of the VT(R),
where R is the expected signal-to noise ratio that is used as the
regularisation parameter (R) in rank-shaping (Fig. 2; (Turkheimer
et al., 2003)).
Methods not requiring an arterial IF
Simpliﬁed reference tissue model using pons as a pseudo-reference tissue.
CB1 receptors are widespread in the brain, and a true reference region
devoid of speciﬁc binding does not exist. A recent attempt to obviate
the invasive procedure of arterial cannulation has been to use the ROI
with the lowest receptor concentration as a pseudo-reference regionFig. 3. Average time activity curves for the pallidum (top) and pons (bottom): the average
compartment (2kbv) model.(Turkheimer et al., 2012). One of the structures with a low concentra-
tion of CB1 receptors is the pons (Yasuno et al., 2008). We therefore
used the pons as a pseudo-reference region in the simpliﬁed reference
tissue model (SRTM).
Modiﬁed standard uptake values (mSUVs). Modiﬁed standard uptake
values (mSUVs; Innis et al., 2007) for frames 25–31, i.e. from 29 min
50 s to 58min 50 s after injection,were also derived for the ROIs accord-
ing to (Gofﬁn et al., 2011):
activity weight kgð Þ þ 70 kg½ =2ð Þ=injected dose: ð4Þ
Global intensities (GI)
Global intensities (GI) were calculated with an in-house script
derived from SPM (Hammers et al., 2007b), where the GI is deﬁned
as the mean voxel value within a mask deﬁned as all voxels exceeding
1/8 of the mean value of all voxels in the image matrix.
Statistical analyses
For statistical testing we used SPSS© for Windows version 16 soft-
ware (IBM 2008, New York, U.S.A.).
Injectate datawere compared between test and retest sessions using
the non-parametric Wilcoxon signed-rank test.
The percentage test–retest difference of parameters obtained with
the variousmethodswas calculated for all subjects in ROIs according to:
2  retest value−test valueð Þ
test valueþ retest value  100: ð5Þ
Reliability was calculated using intraclass correlation coefﬁcients
(Maclennan, 1993):
ICC ¼ MSBS−MSWS
MSBSþ dfWSMSWSð Þ ð6Þ
where MS = mean sum of squares, BS = between-subjects, WS =
within-subjects, and df = degrees of freedom as computed in SPSS,
using the “one-way random” model and reporting the “singleuptake in each region as a function of time in minutes, subsequently ﬁtted with a two-
Table 2
Subjects' volume of distribution (VT) obtained with two-compartment model (2kbv) method. ACG = anterior cingulate gyrus, IFG = inferior frontal gyrus, caudate = caudate
nucleus, pallidum = globus pallidus, accumbens = nucleus accumbens. BS = between-subjects, CV = coefﬁcient of variation, diff = difference, ICC = intraclass correlation coefﬁcient,
Min = minimum, Max = maximum, ROI = region-of-interest, SD = standard deviation.
ROI Median Interquartile range Min Max Median % diff Median % diff range Mean BS % CV ICC
Hippocampus 8.0 6.2–10.8 4.1 24.8 14.8 −54.8–54.2 50.4 0.88
ACG 10.3 7.5–14.0 1.0 26.4 27.8 −154.4–64.2 47.4 0.76
IFG 8.8 7.3–12.3 4.1 22.4 18.1 −48.3–31.9 42.1 0.83
Caudate 7.4 6.0–12.2 3.9 22.9 19.7 −60.9–33.5 48.0 0.85
Pallidum 10.8 8.5–14.2 1.1 32.6 20.6 −158.7–44.1 48.1 0.70
Accumbens 8.4 7.2–13.2 1.2 31.7 35.8 −150.5–51.5 53.7 0.69
Thalamus 5.1 4.4–7.3 2.9 10.9 12.6 −35.5–28.5 35.9 0.89
Pons 3.0 2.8–3.9 2.0 6.2 8.3 −10.7–20.2 30.2 0.95
Mean
(SD)
19.7
(8.7)
44.5
(7.9)
0.82
(0.09)
156 D.A. Riaño Barros et al. / NeuroImage 97 (2014) 151–162measures” ICC. ICC values ≥0.75 were considered indicators of good
reliability (Portney and Watkins, 2009).
We used a Bland–Altman plot to compare methods and assess bias.
In the Bland–Altman plot (also known as Tukey mean-difference plot),
the average of two VT measures for the same region is plotted on
the x-axis, whereas the ﬁrst VT minus the second VT is plotted on
the y axis.
VT x; yð Þ ¼
VT1 þ VT2
2
;VT1−VT2
 
Where quantiﬁcation from two methods is in close agreement and
without bias, the datapoints will be scattered close to y = 0, equally
above and below the x axis. In this case, the 2kbv model was used as
the reference, i.e. VT2 was always the average derived from 2kbv.
The association between percentage test–retest difference and
interscan interval was quantiﬁed for the method yielding the highest
ICCs using Spearman's rho correlation coefﬁcient,with correction formul-
tiple comparisons (8 regions) using the Bonferroni method. The volumes
of distribution between genders were also compared using a repeated
measures full-factorial general linear model, for the same method.
Results
Injectate
Details are given in Table 1. Therewere no signiﬁcant differences be-
tween test and retest studies in terms of the amount of injected radioac-
tivity (median (i.q.r)): test 362 (358–368) MBq; retest 366 (360–372)
MBq; co-injected mass of stable ligand: test: 3.2 (2.4–4.1) μg, retest
3.3 (2.7–4.7) μg; and speciﬁc activity at the time of injection: test 50
(49–61) MBq/ηmol, retest: 51 (37–61) MBq/ηmol.Table 3
Subjects' VT obtained with three-compartment model (4kbv). ACG = anterior cingulate gyru
accumbens = nucleus accumbens. BS = between-subjects, CV = coefﬁcient of variat
Max = maximum, ROI = region-of-interest, SD = standard deviation.
ROI Median Interquartile range Min Max
Hippocampus 13.4 7.5–19.6 −0.7 102.2
ACG 9.0 5.8–13.6 1.4 65.6
IFG 8.9 4.7–11.2 0.8 18.6
Caudate 6.2 4.2–8.5 0.0 31.5
Pallidum 10.6 6.7–18.3 3.4 79.8
Accumbens 13.6 8.7–39.5 0.0 163.5
Thalamus 6.1 4.5–8.4 1.2 30.5
Pons 5.3 3.9–7.2 2.4 23.0
Mean
(SD)Image data
Global intensities of summed radioactivity images did not differ be-
tween test and retest studies (median, interquartile 25th–75th: test:
1.2, 1.0–1.6; retest: 1.3, 1.1–1.5; p N 0.6). Fig. 3 shows examples of
time–activity curves.Quantiﬁcation results
The following sections describe the regional estimates for the pa-
rameters derived with the seven quantiﬁcation methods. To assess
test–retest variation, for each ROI the median percent difference be-
tween test and retest studies as well as their signed range is given in
the tables. The coefﬁcient of variation (standard deviation divided by
the mean) quantiﬁes the between-subject variability of the measure.
The ICC assesses the reliability of the measure as a function of both
within-subject variability and between-subjectvariability; the closer to
the value of 1, the more reliable the method, i.e. the smaller the intra-
subject variability of the measure compared with natural between-
subject variability. Finally, the ratio of the generally highest binding
region (pallidum) over the lowest binding region (pons) assesses a
method's ability to reﬂect known binding heterogeneity.
A comparison of analysis methods and a synthetic overview of the
various measures will be provided in the section “Comparison
between analysis methods”.Compartmental models, requiring arterial IFs
Reversible two-compartment (one tissue compartment) model with vari-
able blood volume (2kbv). The region with the highest VT was globus
pallidus (10.8; Table 2). Regional heterogeneity of VT values was high,
with a ratio of pallidum:pons of 3.6. ICCs ranged between 0.69 and
0.95, with a mean ± SD of 0.82 ± 0.09.s, IFG = inferior frontal gyrus, caudate = caudate nucleus, pallidum = globus pallidus,
ion, diff = difference, ICC = intraclass correlation coefﬁcient, Min = minimum,
Median % diff Median % diff range Mean BS % CV ICC
72.8 −219.9–175.6 81.1 −0.05
53.7 −136.2–126 81.4 0.23
61.1 −159–116.4 51.9 0.13
68.5 −153.4–200.0 69.9 −0.13
69.7 −170.7–126.1 111.3 −0.03
122.1 −72.3–200.0 131.7 −0.06
32.7 −133.8–102.5 87.9 0.49
40.3 −23.4–146.5 79.0 0.50
65.1
(27.1)
86.8
(24.6)
0.14
(0.25)
Table 4
Subjects' volume of distribution (VT) obtained with Spectral Analysis (SA) based on ROI data. ACG = anterior cingulate gyrus, IFG = inferior frontal gyrus, caudate = caudate
nucleus, pallidum = globus pallidus, accumbens = nucleus accumbens. BS = between-subjects, CV = coefﬁcient of variation, diff = difference, ICC = intraclass correlation coefﬁcient,
Min = minimum, Max = maximum, ROI = region-of-interest, SD = standard deviation.
ROI Median Interquartile range Min Max Median % diff Median % diff range Mean BS % CV ICC
Hippocampus 12.4 9.4–17.2 6.6 23.4 10.9 −39.3–29.6 34.1 0.87
ACG 14.4 11.9–19.9 7.3 27.1 12.4 −64.3–39.3 35.0 0.74
IFG 13.9 10.1–19.3 5.4 26.3 13.3 −76.3–47.3 39.0 0.71
Caudate 13.0 9.3–19.4 5.9 28.1 13.6 −80.8–26.3 44.2 0.74
Pallidum 15.7 12–21.7 8.2 28.9 9.4 −53.8–33.5 35.5 0.85
Accumbens 13.9 11.3–18.9 6.9 26.7 15.1 −63.6–47.1 35.2 0.80
Thalamus 9.6 6.9–12.2 4.8 20.3 24.7 −60.7–49.2 39.4 0.70
Pons 6.0 4.6–7.1 2.9 11.8 24.8 −62.0–39.9 35.5 0.67
Mean
(SD)
15.5
(6.0)
37.2
(3.4)
0.76
(0.07)
157D.A. Riaño Barros et al. / NeuroImage 97 (2014) 151–162Reversible three-compartment (two tissue compartment) model with
variable blood volume (4kbv). The method yielded highly variable data.
Unlike for the other methods, the regions with the highest VT values
were nucleus accumbens (13.6; Table 3) and hippocampus (13.4). The
ratio of pallidum/pons was 2.0. ICCs ranged between−0.13 and 0.50,
with a mean ± SD of 0.14 ± 0.25.
Model-free analyses, requiring arterial IFs
Directly obtaining VT values from ROI data with “classic” spectral analysis
(SA). The region with the highest VT values was globus pallidus (15.7;
Table 4). Regional heterogeneity of VT values, estimated as the ratio of
pallidum over pons, was 2.6. ICCs ranged between 0.67 and 0.87, with
a mean ± SD of 0.76 ± 0.07.
Sampling parametric VT images obtained with “classic” spectral analysis.
The regionwith the highest VTwas the pallidum (15.8; Table 5). Region-
al heterogeneity of VT values was moderate, with a ratio of pallidum
over pons of 3.6. ICCs were fairly homogenous between regions and
ranged between 0.76 and 0.87, with a mean ± SD of 0.83 ± 0.03.
Fig. 4 shows an example of a parametric map.
Spectral analysis with rank shaping regularisation. The region with the
highest VT values was globus pallidus (10.3; Table 6). Regional hetero-
geneity of VT values was lower than with the preceding methods, with
a ratio of pallidum over pons of 2.4. ICCs ranged between 0.73 and
0.90, with a mean ± SD of 0.82 ± 0.05.
Methods not requiring an arterial IF
SRTM with pons as a pseudo-reference tissue. The method yielded
inconsistent data. The regions with the highest values were the
globus pallidus, the anterior cingulate gyri, and the nucleus accumbens
(BPND = 1.1; Table 7). The ratio of pallidum over pons could not beTable 5
Subjects' volume of distribution (VT) obtained with “classic” spectral analysis (SA) on parametr
nucleus, pallidum = globus pallidus, accumbens = nucleus accumbens. BS = between-subjec
Min = minimum, Max = maximum, ROI = region-of-interest, SD = standard deviation.
ROI Median Interquartile range Min Max
Hippocampus 11.5 9–16.2 7.0 22.6
ACG 14.8 11.1–20.5 8.1 28.8
IFG 14.8 10.4–20.3 7.6 27.6
Caudate 12.9 10.2–19.3 6.5 26.9
Pallidum 15.8 11.6–21.1 8.6 30.4
Accumbens 9.5 7.8–13.9 5.3 18.7
Thalamus 13.2 10.4–17.3 5.2 26.5
Pons 4.4 3.5–5.3 1.7 9.6
Mean
(SD)calculated, as the BPND of pons as the reference region is ~0. ICCs ranged
between−0.29 and 0.50, with a mean ± SD of 0.07 ± 0.27.
Modiﬁed standard uptake values (mSUVs). The region with the highest
values was globus pallidus (3.6; Table 8). Regional heterogeneity of
values was the highest of all methods tested with the ratio of pallidum
over pons 4.2. ICCs ranged from 0.47 to 0.86, with a mean ± SD of
0.79 ± 0.13.
Comparison between analysis methods
Relative to the 2kbv model, a bias towards overestimation of medi-
um high hippocampal VT of [11C]MePPEP was seen for both analyses
using “classic” SA (Fig. 5). RS-SA did not show this bias but restricted
the range of VT estimates, with an underestimation of the highest VTs.
The 4kbv model was not assessed due to its lack of reliability.
Table 9 provides an overview of the median test–retest differences
(%) for the different methods. 2kbv and the methods using SA had me-
dian differences between 13 and 20%, similar across regions as indicated
by low spreads (SDs), whilst mSUVs varied even less on average, but
with more between-region variation due to the pons showing high
test–retest differences (37%). 4kbv and SRTM were very variable for
most regions.
Mean between-subject coefﬁcients of variation (BSCV; %) for the dif-
ferent methods are listed in Table 10. The between-subject variability
based onmSUVs (i.e. tissue data only)was approximately 32%; however
the BSCV for pons was 63%. The three methods based on SA had similar
between-subject variation, around 36%, with similar variability for the
various regions. Between-subject variability was higher for the 2kbv
compartmental model, at 45%. SRTM and the 4kbv model yielded im-
plausible values.
ICCs for all methods are listed in Table 11. As expected from the high
test–retest variability (Table 9) and unrealistically high between-subject
variability (Table 10), the 4kbv model and SRTM yielded non-ic maps. ACG = anterior cingulate gyrus, IFG = inferior frontal gyrus, caudate = caudate
ts, CV = coefﬁcient of variation, diff = difference, ICC = intraclass correlation coefﬁcient,
Median % diff Median % diff range Mean BS % CV ICC
9.6 −40.1–20.6 34.2 0.87
12.5 −44.0–30.1 34.7 0.85
12.0 −49.7–27.0 37.0 0.85
12.3 −76.6–24.3 40.0 0.81
12.6 −53.0–23.5 35.4 0.83
12.3 −44.6–31.4 36.0 0.83
16.8 −78.9–50.8 37.1 0.76
20.2 −33.1–43.3 39.0 0.81
13.5
(3.3)
36.7
(2.0)
0.83
(0.03)
Fig. 4. Example of a parametric map, co-registered onto the subject's MRI scan. Left, sagittal; middle, coronal; right, transverse. Note high binding in the putamen and pallidum and inter-
mediate binding in the hippocampus and thalamus. Colour bar: VT values. P, posterior; A, anterior; R, right; L, left.
Table 6
Subjects' Volume of distribution (VT) obtained with Rank Shaping (RS) regularisation of Spectral Analysis (SA) method. ACG = anterior cingulate gyrus, IFG = inferior frontal gyrus,
caudate = caudate nucleus, pallidum = globus pallidus, accumbens = nucleus accumbens. BS = between-subjects, CV = coefﬁcient of variation, diff = difference, ICC = intraclass
correlation coefﬁcient, Min = minimum, Max = maximum, ROI = region-of-interest, SD = standard deviation.
ROI Median Interquartile range Min Max Median % diff Median % diff range Mean BS % CV ICC
Hippocampus 8.2 5.8–10.4 4.2 15.2 14.4 −48.5–34.9 35.9 0.81
ACG 9.9 7.6–13.7 5.5 18.8 14.6 −29.7-32.4 34.0 0.86
IFG 9.9 7.2–13.8 5.3 18.2 15.6 −39.5-29.0 34.8 0.85
Caudate 8.1 6.1–12.6 4.4 18.1 11.6 −88.7-27.0 42.2 0.82
Pallidum 10.3 7.0–13.0 4.5 20.7 23.3 −64.1-42.3 39.7 0.77
Accumbens 8.6 6.1–10.5 3.2 15.9 18.5 −77.8-58.4 36.5 0.73
Thalamus 6.5 5.5–9.4 3.5 12.7 14.9 −43.9-31.0 34.7 0.85
Pons 4.3 3.3–5.3 2.5 8.0 7.4 −30.6-24.1 32.3 0.90
Mean
(SD)
15.0
(4.7)
36.3
(3.2)
0.82
(0.05)
158 D.A. Riaño Barros et al. / NeuroImage 97 (2014) 151–162reproducible results, as reﬂected by an ICC around zero. All the other
methods had good to very good reproducibility, ranging from 0.76 ±
0.07 for classic SA calculated on ROI data to 0.83 ± 0.04 for classic SA ap-
plied to parametric maps. Note the low between-region spread of the ICC
for theﬁvemethodswith goodor very good reproducibility,meaning that
reproducibility was good throughout the brain regions sampled.
Table 11 also shows the ratio between a high-binding region
(pallidum) and a low-binding region (pons), indicating amethod's abil-
ity to reﬂect the known between-region heterogeneity. mSUVs had the
highest differential, followed by 2kbvmodel and SA applied to paramet-
ric maps.
A positive correlation was observed for test–retest difference and
interscan interval in the inferior frontal gyrus (p = 0.039, Spearman's
rho = 0.538) and the caudate (p = 0.033, Spearman's rho = 0.550).
These correlations were rendered insigniﬁcant by correction forTable 7
Subjects' binding potential (BPND) obtained with the SRTM and pons as a pseudo-reference reg
cleus, pallidum = globus pallidus, accumbens = nucleus accumbens. BS = between-subjects
Min = minimum, Max = maximum, ROI = region-of-interest, SD = standard deviation.
ROI Median BPND Interquartile range Min Max
Hippocampus 1.0 0.8–1.7 0.4 12.8
ACG 1.1 0.9–1.2 0.7 3.4
IFG 0.9 0.9–1.0 0.0 1.7
Caudate 0.9 0.6–1.0 0.2 2.7
Pallidum 1.1 1.0–1.3 0.1 1.6
Accumbens 1.1 0.7–1.6 −0.2 18.2
Thalamus 1.0 0.5–6.2 0.4 10.4
Mean
(SD)multiple comparisons. There was no signiﬁcant inﬂuence of gender on
the VTs (F = 27.349, p = 0.995). There was no signiﬁcant interaction
between gender and test–retest condition (p = 0.120).
Discussion
We describe the test–retest reproducibility of quantiﬁcation for
CB1-receptor availability, as assessed by [11C]MePPEP PET, in 15
healthy human subjects. Ourmajor ﬁnding is that good-to-excellent re-
producibility of estimates of availability is achievable using either the
one tissue compartment, two rate-constant kinetic model with a vari-
able blood volume term; model-free analyses using spectral analysis
variants; or simple scaled measures of radioactivity (mSUV).
The performance of the various methods was consistent between
measures — those having low percentage test–retest variability alsoion. ACG = anterior cingulate gyrus, IFG = inferior frontal gyrus, caudate = caudate nu-
, CV = coefﬁcient of variation, diff = difference, ICC = intraclass correlation coefﬁcient,
Median % diff. Median % diff range Mean %BS-CV ICC
54.6 −155.5–176.6 125.2 −0.06
40.2 −142.9–71.7 −574.1 0.50
16.0 −66.6–207.6 29.4 −0.29
30.5 −137.5–45.4 48.8 0.06
9.4 −37.9–158.4 25.1 0.27
53.0 −213.9–180.6 157.4 −0.15
42.3 −169.8–181.2 108.2 0.19
35.1
(17.4)
0.07
(0.27)
Table 8
Subjects' modiﬁed standard uptake values (mSUV). ACG = anterior cingulate gyrus, IFG = inferior frontal gyrus, caudate = caudate nucleus, pallidum = globus pallidus,
accumbens = nucleus accumbens. BS = between-subjects, CV = coefﬁcient of variation, diff = difference, ICC = intraclass correlation coefﬁcient, Min = minimum,
Max = maximum, ROI = region-of-interest, SD = standard deviation.
ROI Median Interquartile range Min Max Median % diff. Median % diff range Mean %BS-CV ICC
Hippocampus 2.7 2.1–3.2 1.8 4.2 8.3 −22.6–34.4 27.4 0.84
ACG 3.2 2.6–3.8 2.0 5.2 8.8 −24.1–32.7 27.2 0.86
IFG 3.2 2.6–3.7 2.1 5.3 8.9 −22.4–35.1 27.3 0.86
Caudate 2.9 2.5–3.9 1.9 5.1 7.6 −58.1–30.3 30.1 0.79
Pallidum 3.6 2.7–4.1 2.2 5.5 11.1 −28.6–30.9 27.1 0.84
Accumbens 3.0 2.4–3.6 1.5 4.7 6.7 −65.7–33.7 27.9 0.80
Thalamus 2.7 2.2–3.2 1.7 4.3 8.1 −16.7–38.1 25.8 0.83
Pons 0.9 0.6–1.3 0.3 3.4 36.7 7.3–108.2 62.6 0.47
Mean
(SD)
12.0
(10.1)
31.9
(12.5)
0.79
(0.13)
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Fig. 5. Bland–Altman plot for the different methods to obtain VTs. Data for the hippocampus is shown as an example, relative to the one compartment, two-rate constant model
(blue diamonds, 2kbv); green triangles: rank-shaping regularisation of spectral analysis; red squares: “classic” voxel-wise SA; and purple circles: “classic” SA on ROI data.
159D.A. Riaño Barros et al. / NeuroImage 97 (2014) 151–162had high ICCs, reﬂecting that among the well-performing methods,
between-subject variability was comparable.
The 2kbv compartmental model was among the best performing
methods for test–retest variability and reliability, and also had one of
the highest ratios of pallidum over pons. This indicates low bias (i.e. a
large range of concentrations between regions of known high and lowTable 9
Median test–retest differences (%) for subjects' parameter estimates (VT/BPND/mSUV) obtained
caudate = caudate nucleus, pallidum = globus pallidus, accumbens = nucleus accumbens. R
Method 2kbv 4kbv SA-ROIs S
Parameter VT VT VT V
Sampling ROI on dynamic
images
ROI on dynamic
images
ROI on dynamic
images
R
m
Hippocampus 14.8 72.8 10.9 9
ACC 27.8 53.7 12.4 1
IFG 18.1 61.1 13.3 1
Caudate 19.7 68.5 13.6 1
Pallidum 20.6 69.7 9.4 1
Accumbens 35.8 122.1 15.1 1
Thalamus 12.6 32.7 24.7 1
Pons 8.3 40.3 24.8 2
Mean ± SD 19.7 ± 8.7 65.1 ± 27.1 15.5 ± 5.9 1receptor availability). This ratio was lower for the spectral analysis var-
iants applied to ROI data, reﬂecting their known bias towards lower VT
estimates in high binding regions (Hammers et al., 2007a). In contrast,
voxel-wise SA had the same high pallidum/pons ratio as the 2kbv
model. This may be due to SA's ability to ﬁt voxel-wise time courses —
voxels with varying partial volume contributions of white matter orwith the different methods. ACG = anterior cingulate gyrus, IFG = inferior frontal gyrus,
OI = region-of-interest, SD = standard deviation.
A-maps RS-SA SRTM mSUV
T VT BPND kBq/ml
OI on parametric
aps
ROI on dynamic
images
ROI on dynamic
images
ROI on summed
images
.6 14.4 54.6 8.3
2.5 14.6 40.2 8.8
2.0 15.6 16.0 8.9
2.3 11.6 30.5 7.6
2.6 23.3 9.4 11.1
2.3 18.5 53.0 6.7
6.8 14.9 42.3 8.1
0.2 7.4 NA 36.7
3.5 ± 3.3 15.0 ± 4.6 35.1 ± 17.4 12.0 ± 10.1
Table 10
Mean between-subject coefﬁcients of variation (BSCV; %) for subjects' VT/BPND/mSUV parameters obtained with the different methods. ACG = anterior cingulate gyrus, IFG = inferior
frontal gyrus, caudate = caudate nucleus, pallidum = globus pallidus, accumbens = nucleus accumbens. ROI = region-of-interest, SD = standard deviation, NA = not applicable.
Method 2kbv 4kbv SA-ROIs SA-maps RS-SA SRTM mSUV
Parameter VT VT VT VT VT BPND kBq/ml
Sampling ROI on dynamic
images
ROI on dynamic
images
ROI on dynamic
images
ROI on parametric
maps
ROI on dynamic
images
ROI on dynamic
images
ROI on summed
images
Hippocampus 50.4 81.1 34.1 34.2 35.9 125.2 27.4
ACG 47.4 81.4 35.0 34.7 34.0 −574.1 27.2
IFG 42.1 51.9 39.0 37.0 34.8 29.4 27.3
Caudate 48.0 69.9 44.2 40.0 42.2 48.8 30.1
Globus Pallidum 48.1 111.3 35.5 35.4 39.7 25.1 27.1
Accumbens 53.7 131.7 35.2 36.0 36.5 157.4 27.9
Thalamus 35.9 87.9 39.4 37.1 34.7 108.2 25.8
Pons 30.2 79.0 35.5 39.0 32.3 NA 62.6
Mean ± SD 44.5 ± 7.9 86.8 ± 24.6 37.2 ± 3.4 36.7 ± 2.0 36.3 ± 3.2 −11.4 ± 253.2 31.9 ± 12.5
160 D.A. Riaño Barros et al. / NeuroImage 97 (2014) 151–162vasculature can be individually ﬁtted, which is not the case for methods
using the averaged ROI TAC.
Several, but not all (e.g. Ahmad et al., 2014; Gofﬁn et al., 2011; Van
Laere et al., 2010), earlier in vivo human studies with [18F]MK-9470
(Burns et al., 2007), [11C]MePPEP (Terry et al., 2009) and [18F]FMPEP-d2
(Terry et al., 2010b) involved 120 to 300 min scan times (Terry et al.,
2009, 2010). This requirement limits the usefulness of these authors' ap-
proaches, as patients with debilitating conditions and even healthy vol-
unteers are unlikely to tolerate PET scans of 2 h duration or more. Here
wepresent data that indicates thatwith [11C]MePPEP, reliable quantiﬁca-
tion of CB1 receptor availability is achievable with just 90 min of data ac-
quisition. In a previous study, it has been shown that 90 min of
acquisition is sufﬁcient for obtaining stable VT estimates (Terry et al.,
2009).
In addition, the injected doses used in previous studies were gener-
ally approximately twice as high as the doses used in our study, up to
750 MBq of [11C]MePPEP (Terry et al., 2009). We achieved reliable re-
ceptor availability estimation using only 370MBq, entailing an effective
dose of just ~1.7 mSv per scan (Terry et al., 2010a). We had previously
observed that both image quality and the reliability of blood data mea-
surements were lower when injected doses of a radioligand with simi-
larly slow kinetics were lowered to ~180 MBq (Hammers et al.,
2007a). In our hands,mSUVs – using only tissue data – yielded excellent
test–retest properties and differentiation between regions, with the
highest pallidum/pons ratio of all methods. The fact that excellent reli-
ability and differentiation between regions with high and low receptor
concentrations (Herkenham et al., 1990) could be achieved with
methods using metabolite-corrected arterial plasma input functions
suggests the reliability of the blood measurements.Table 11
Intraclass correlation coefﬁcients (ICCs) for subjects' volume of distribution (VT) and/or binding
(pallidum) over that of a low-binding region (pons) is also given. ACG = anterior cingulate gy
accumbens = nucleus accumbens. ROI = region-of-interest, SD = standard deviation, NA =
Method 2kbv 4kbv SA-ROIs
Parameter VT VT VT
Sampling ROI on dynamic
images
ROI on dynamic
images
ROI on dynamic
images
Hippocampus 0.88 −0.05 0.87
ACG 0.76 0.23 0.74
IFG 0.83 0.13 0.71
Caudate 0.85 −0.13 0.74
Pallidum 0.70 −0.03 0.85
Accumbens 0.69 −0.06 0.80
Thalamus 0.89 0.49 0.70
Pons 0.95 0.50 0.67
Mean ± SD 0.82 ± 0.09 0.14 ± 0.25 0.76 ± 0.07
Ratio pallidum/pons 3.6 2.0 2.6Because arterial cannulations require skilled personnel and involve
discomfort and small risks to volunteers and patients, non-invasive
PET studies are usually preferred in research studies, and even more
so in a clinical environment. Methods using a reference region devoid
of the studied receptor are needed for full quantiﬁcation in the absence
of an input function. However, CB1 receptors are present throughout the
brain, and a true reference region does not exist. Here we used the pons
as a pseudo-reference region. It has low CB1 receptor concentration
(Herkenham et al., 1990; Irving et al., 2002; Terry et al., 2009; Yasuno
et al., 2008), motivating this attempt despite some speciﬁc binding
(Terry et al., 2009; Yasuno et al., 2008). We were unable to achieve re-
liable data. The application of more sophisticated pseudo-reference re-
gion approaches as described in recent studies (Turkheimer et al.,
2012) might improve on these results. However, we note that the
pons tissue data (i.e. mSUV) measurements were far less reliable than
measurements elsewhere. Even small variations in the amount of spe-
ciﬁc binding between individuals may thus have a large inﬂuence on
the radioactivity concentration in this region, with resulting low reli-
ability for the SRTM.
This is the ﬁrst study to applymodel-free analyses (spectral analysis
with or without rank shaping regularisation) to quantify cannabinoid
receptor availability using [11C]MePPEP PET. These have the advantage
of being ‘data-driven’ rather than requiring an a priori model selection.
We additionally describe the ﬁrst voxel-wise quantiﬁcation of [11C]
MePPEP, yielding parametric VT images with high corresponding re-
gional ICCs. Spectral analysis does not require a priori assumptions re-
garding the number of components, compartments, or distribution of
receptors. Spectral analysis estimations require compartmental systems
that are strongly connected, have exchange of material with thepotential (BP) obtainedwith thedifferentmethods. The ratioVT/BP of a high binding region
rus, IFG = inferior frontal gyrus, caudate = caudate nucleus, pallidum = globus pallidus,
not applicable.
SA-maps RS-SA SRTM mSUV
VT VT BPND kBq/ml
ROI on parametric
maps
ROI on dynamic
images
ROI on dynamic
images
ROI on summed
images
0.87 0.81 −0.06 0.84
0.85 0.86 0.50 0.86
0.85 0.85 −0.29 0.86
0.81 0.82 0.06 0.79
0.83 0.77 0.27 0.84
0.83 0.73 −0.15 0.80
0.76 0.85 0.19 0.83
0.81 0.90 NA 0.47
0.83 ± 0.03 0.82 ± 0.05 0.07 ± 0.27 0.79 ± 0.13
3.6 2.4 NA 4.2
161D.A. Riaño Barros et al. / NeuroImage 97 (2014) 151–162environment conﬁned to a single compartment, and do not contain cy-
cles, i.e., there is no possibility for material to pass from one compart-
ment through two or more compartments back to the initial
compartment (Schmidt, 1999). SA cannot be used to estimate reference
regionmodels because the ﬁt assumes a sum of positive series of convo-
lution integrals of the input function. This last condition is relaxed in
Rank-Shaping SA.
We do not expect any biases when spectral analysis is applied to
data from participants who are not healthy controls. SA has been used
successfully in several patient populations.
The improved ICCmeasures of SAmethodologies over compartmen-
tal ones indicate a complex compartmentalisation of the underlying re-
ceptor distribution. CB1 receptors can be found on neurons, astrocytes,
and also the vascular endothelium. Compartmental models usually as-
sume that a single concentration represents the free-in-tissue tracer
compartment. This concentration in reality is the average of concentra-
tions of the free radioligand in different tissue environments, as there
will be a gradient across different cellular elements. This will cause an
apparent change in afﬁnity of the tracer depending on the target cell
(Delforge et al., 1996). Spectral analysis, which does not depend on a
free compartmental structure, has more ﬂexibility in dealing with
such a complex signal.
A major difference relative to the previous test–retest study (Terry
et al., 2009) is the lack of reliability of VT estimates obtained with the
two-tissue compartmentmodel (4kbv) in our study, as well as good re-
liability for VT estimates obtained using the one-tissue compartment
model 2kbv, whereas this had yielded poor ﬁts for Terry et al. (2009).
This might relate to longer scanning time and nearly twice the injected
dose in the former study. An additional major difference in themodels is
that we estimated the blood volume contribution, whereas this had been
set to 5% in theprevious study. Of note, for a similar time interval our stan-
dardized uptake values are comparable to those of Terry et al. (2009).
We did not collect data from the female participants concerning the
stage of their menstrual cycle on the day of scanning. Here, when this
was tested for the “classic” spectral analysis (parametricmaps)method,
there was no signiﬁcant between-subject inﬂuence of gender on the
VTs; nor was there a signiﬁcant interaction between gender and test–re-
test condition. Whilst further investigation is required, we therefore
hypothesise that the menstrual cycle has a minimal effect on the vari-
ability of [11C]MePPEP VT in human females.
We did not calculate the parent tracer free fraction, which may be
important (Terry et al., 2010a; Terry et al., 2010b; Yasuno et al., 2008).
However, our result of good reproducibility with tissue-only data
(mSUV) and even better reproducibility with modelling approaches
using the arterial input data suggests that this omission did not have
an adverse effect.
In conclusion, quantiﬁcation of CB1 receptor availability showed
good-to-excellent reproducibility with selected kinetic and model-free
analyses, whether applied on a region-of-interest or voxel-wise basis.
[11C]MePPEP PET is well-placed as a tool to investigate CB1 receptor-
mediated neurotransmission in health and neuropsychiatric disease.Acknowledgments
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